Paper39335671
Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy.
Ghemrawi R and 7 others. Biomedicines, 2024. Cited by 66 papers, by iCite.
Cite this record
ConductScience Library. Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy. Papers, record 39335671. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39335671
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References177
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37896162 | Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/37896162 | PubMed |
| 2 | 38139301 | Advances in Targeted Immunotherapy in Cancers. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38139301 | PubMed |
| 3 | 29869168 | Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies. | Cancer Immunol Immunother | 2018 | https://conductscience.org/library/papers/29869168 | PubMed |
| 4 | 21768293 | Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. | Blood | 2011 | https://conductscience.org/library/papers/21768293 | PubMed |
| 5 | 18073223 | Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. | Protein Eng Des Sel | 2008 | https://conductscience.org/library/papers/18073223 | PubMed |
| 6 | 27435312 | A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy. | J Transl Med | 2016 | https://conductscience.org/library/papers/27435312 | PubMed |
| 7 | 33802331 | Recent Advancements on Immunomodulatory Mechanisms of Resveratrol in Tumor Microenvironment. | Molecules | 2021 | https://conductscience.org/library/papers/33802331 | PubMed |
| 8 | 11825563 | Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. | Immunity | 2002 | https://conductscience.org/library/papers/11825563 | PubMed |
| 9 | 32698317 | Monoclonal Antibodies in Cancer Therapy. | Antibodies (Basel) | 2020 | https://conductscience.org/library/papers/32698317 | PubMed |
| 10 | 35794202 | A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron. | Commun Biol | 2022 | https://conductscience.org/library/papers/35794202 | PubMed |
| 11 | 16155579 | Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. | Nat Med | 2005 | https://conductscience.org/library/papers/16155579 | PubMed |
| 12 | 30214153 | A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities. | Drug Des Devel Ther | 2018 | https://conductscience.org/library/papers/30214153 | PubMed |
| 13 | 38149884 | Recent Advances in the Development of Monoclonal Antibodies and Next-Generation Antibodies. | Immunohorizons | 2023 | https://conductscience.org/library/papers/38149884 | PubMed |
| 14 | 29462558 | Molecular Imaging of Mesothelin-Expressing Ovarian Cancer with a Human and Mouse Cross-Reactive Nanobody. | Mol Pharm | 2018 | https://conductscience.org/library/papers/29462558 | PubMed |
| 15 | 28029927 | Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. | N Engl J Med | 2016 | https://conductscience.org/library/papers/28029927 | PubMed |
| 16 | 37681891 | Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review. | Cells | 2023 | https://conductscience.org/library/papers/37681891 | PubMed |
| 17 | 31921205 | The Intriguing History of Cancer Immunotherapy. | Front Immunol | 2019 | https://conductscience.org/library/papers/31921205 | PubMed |
| 18 | 25632005 | A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells. | J Immunol | 2015 | https://conductscience.org/library/papers/25632005 | PubMed |
| 19 | 31894001 | Development of therapeutic antibodies for the treatment of diseases. | J Biomed Sci | 2020 | https://conductscience.org/library/papers/31894001 | PubMed |
| 20 | 35392964 | Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. | Cell Commun Signal | 2022 | https://conductscience.org/library/papers/35392964 | PubMed |
Cited by53
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 66 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42920849 | Progress on therapeutic mRNA vaccines for cancer. | Front Oncol | 2026 | https://conductscience.org/library/papers/42920849 | PubMed |
| 42840090 | Immune checkpoint inhibitor-related myotoxicity in lung cancer: a decade-long real-world pharmacovigilance analysis of the FAERS database. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42840090 | PubMed |
| 42814277 | Recent advancements and persisting challenges in the evolution of next generation car t cell therapy for solid malignancies: a comprehensive review. | Immunol Res | 2026 | https://conductscience.org/library/papers/42814277 | PubMed |
| 42797543 | Engineering Functional Biomaterials for Targeted and Localized Cancer Drug Delivery: A Structure-Property-Performance Design Perspective. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42797543 | PubMed |
| 42749398 | mRNA-based therapeutics in lung Cancer: Mechanisms, applications, and translational challenges. | J Genet Eng Biotechnol | 2026 | https://conductscience.org/library/papers/42749398 | PubMed |
| 42689115 | The Cancer Epitope Database and Analysis Resource (CEDAR): current capabilities and future directions. | Front Oncol | 2026 | https://conductscience.org/library/papers/42689115 | PubMed |
| 42677342 | Integrating AI, RNA Vaccines, and CAR-T Cells for Personalized Treatment. | J Immunol Res | 2026 | https://conductscience.org/library/papers/42677342 | PubMed |
| 42624898 | Advanced gene editing technologies for oncology mechanisms, applications, and clinical implementation. | Cancer Gene Ther | 2026 | https://conductscience.org/library/papers/42624898 | PubMed |
| 42559290 | Antibody-Drug Conjugates and Peptide-Drug Conjugates: Current Understandings and Future Perspectives. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42559290 | PubMed |
| 42380303 | Integrating artificial intelligence into small molecule development for precision cancer immunomodulation therapy. | NPJ Drug Discov | 2025 | https://conductscience.org/library/papers/42380303 | PubMed |
| 42338900 | Glucan-Based Nanoparticles Empower Precision Cancer Immunotherapy: Design Strategies, Immune Reprogramming Mechanisms, and Clinical Translation Prospects. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42338900 | PubMed |
| 42243936 | Clinical application of cytokine-induced killer cells in cancer immunotherapy. | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/42243936 | PubMed |
| 42237149 | Immunoinformatics-guided design of a multi-epitope vaccine targeting WISP1 for gastric cancer. | BMC Biotechnol | 2026 | https://conductscience.org/library/papers/42237149 | PubMed |
| 42191970 | Production of monoclonal antibodies (mAbs) against oralcarcinoma & its bioconjugation with solid lipid nanoparticles (SLN) for drug delivery. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42191970 | PubMed |
| 41971016 | Role of circular RNAs in regulating toxicity induced by cancer therapies. | Genes Dis | 2026 | https://conductscience.org/library/papers/41971016 | PubMed |
| 41933234 | Emerging nanoimmunotherapeutic strategies for breast cancer. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41933234 | PubMed |
| 41870184 | The Trifecta of Polo-Like Kinases, Cancer, and the Immune System: Emerging Intersections and Therapeutic Insights. | Mol Cancer Res | 2026 | https://conductscience.org/library/papers/41870184 | PubMed |
| 41836358 | Crosstalk between autophagy and apoptosis in initiating antitumor immune responses in human lymphoma cells. | Explor Immunol | 2025 | https://conductscience.org/library/papers/41836358 | PubMed |
| 41657772 | Natural compounds in ovarian cancer: mechanistic insights and therapeutic potential. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41657772 | PubMed |
| 41634702 | The molecular mechanism of IGF2BP3 promoting the malignant progression of lung cancer. | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/41634702 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| NR1I3 | 9970 | PubTator's text mining | https://conductscience.org/library/genes/9970 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39335671
GET https://conductscience.org/api/papers/v1/39335671/references?page=2